Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376734 · ClinicalTrials.gov registry record · Phase 2
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
A Phase 2 study of Schizophrenia and Major Depressive Disorder, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT06376734: Recruiting Phase 2 study of Schizophrenia and Major Depressive Disorder, sponsored by Brigham and Women's Hospital.
NCT06376734 is a Phase 2 study of Schizophrenia and Major Depressive Disorder that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 180 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376734, a Phase 2 study of Schizophrenia and Major Depressive Disorder, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
Primary Outcome
The primary outcome is that stimulation of different circuits will selectively modify different behavioral clusters. Participants will complete the following phenotyping battery tasks and questionnaires: Q-SCID PANSS SAPS SANS PYRATS CDSS YBOCS CGI ATQ ASI BAI BDI BIS/BAS Claremont Purpose Scale De Jong Gierveld Loneliness Scale Daily Spiritual Experience Scale Emotional Reactivity Scale Flourishing Measures Headache Impact Test HiTOP-Self Report Moral Judgment Scale Pain Screener Personal Rela
Conditions Studied
Interventions
- DEVICE Transcranial magnetic stimulation
Study Locations (2)
California
- Acacia Clinics - Sunnyvale
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 2 |
What NCT06376734 shows while recruiting
NCT06376734 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% lower).
The record links to 8 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Transcranial magnetic stimulation is the first listed.
NCT06376734 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06376734 about?
NCT06376734 is a clinical study titled "Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness". Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
What is the current status of trial NCT06376734?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-01-30. Estimated completion is 2030-06-01.
What conditions does trial NCT06376734 study?
This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Obsessive - Compulsive Disorder, Generalized Anxiety Disorder, Depression, Anxiety.
What interventions are being tested in trial NCT06376734?
The interventions under investigation include: Transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT06376734?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376734 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06376734's enrollment target sits among peer trials
180 93rd of 315 higher than 223 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
A Study of ANAVEX3-71 in Adults With Schizophrenia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI